Zilberberg, M.D.; Nathanson, B.H.; Redell, M.A.; Sulham, K.; Shorr, A.F.
Comparative Outcomes of Meropenem–Vaborbactam vs. Ceftazidime–Avibactam Among Adults Hospitalized with an Infectious Syndrome in the US, 2019–2021. Antibiotics 2025, 14, 29.
https://doi.org/10.3390/antibiotics14010029
AMA Style
Zilberberg MD, Nathanson BH, Redell MA, Sulham K, Shorr AF.
Comparative Outcomes of Meropenem–Vaborbactam vs. Ceftazidime–Avibactam Among Adults Hospitalized with an Infectious Syndrome in the US, 2019–2021. Antibiotics. 2025; 14(1):29.
https://doi.org/10.3390/antibiotics14010029
Chicago/Turabian Style
Zilberberg, Marya D., Brian H. Nathanson, Mark A. Redell, Kate Sulham, and Andrew F. Shorr.
2025. "Comparative Outcomes of Meropenem–Vaborbactam vs. Ceftazidime–Avibactam Among Adults Hospitalized with an Infectious Syndrome in the US, 2019–2021" Antibiotics 14, no. 1: 29.
https://doi.org/10.3390/antibiotics14010029
APA Style
Zilberberg, M. D., Nathanson, B. H., Redell, M. A., Sulham, K., & Shorr, A. F.
(2025). Comparative Outcomes of Meropenem–Vaborbactam vs. Ceftazidime–Avibactam Among Adults Hospitalized with an Infectious Syndrome in the US, 2019–2021. Antibiotics, 14(1), 29.
https://doi.org/10.3390/antibiotics14010029